3 October 2022 in Contemporary Clinical Trials Communications
RAReginald Roland Amponsah
+1
Clinical trials are an essential part of drug and vaccine development, as well as the development of new biomedical devices, and medical procedures. Successful enrolment of human volunteers is important to the success of any clinical trial anywhere around the globe. Enrolment is however affected by a number of factors including knowledge, attitudes, and perceptions (KAPs). We aimed to determine factors that are deemed important in improving participation in clinical trials within a Ghanaian community. This was a cross-sectional study that employed a structured questionnaire within the New Juaben South Municipal Assembly (NJSMA). Participants who were 18 years and above were included in this study. There were a total of 639 participants in this study. Participants’ demographics were collected and various questions were asked to assess their KAP towards participation in clinical trials. The mean age of participants was 29.03 ± 8.95 years, there were more males (51.96%) than females, 42.35% had tertiary education, 38.03% were artisans, 74.80% were Christians and 14.40% had previously participated in a clinical trial. Participants had average knowledge about clinical trials (CT) with a mean score of 7.56 ± 1.76 (63%). A significant association between knowledge levels and education was observed (χ2 = 100.3, p < 0.0001). Helping in advancing the medical knowledge was the key reason for participation in CT while mistrust of the medical system was the key setback in participation in CT. There was a generally positive attitude and a neutral perception towards participation in CTs. Groups intending to conduct CT should highlight the benefits of CT and address the perception of mistrust in the conduct of CTs in their education and sensitization programs before initiation of CTs in Ghana.
21 May 2026 in Endocrinology, Diabetes & Metabolism
Introduction: Several challenges have been raised about the ability of urine microalbumin and eGFR to sufficiently diagnose nephropathy, especially in the early stages. Emerging evidence suggests that podocyte‐associated biomarkers, along with routine haemato‐biochemical parameters, may offer a more accurate and cost‐effective diagnostic alternative. This study, therefore, assessed the performance of podocyte markers and inexpensive haemato‐biochemical parameters in the diagnosis of diabetic nephropathy. Methods: This unmatched 1:1 case–control study included 134 people living with diabetes (PLWD) as cases and 134 people without diabetes (PwD) as controls. Blood samples were collected from participants for full blood count and separated serum and urine for ELISA quantification of podocyte markers. This study was designed and reported based on the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist for case–control studies. Statistical analyses were performed using SPSS 26.0 and R Language 4.4.4 at a significant level of 0.05% and 95% confidence interval. Results: This study found macroalbuminuric PLWD had significantly low mean cell volume, but significantly higher levels of platelet and mean platelet volume. Moreover, nephrin and podocalyxin levels were significantly higher in subjects with microalbuminuria and macroalbuminuria compared to PwD nephropathy subjects. Increasing nephrin levels (AUC = 0.774, p = 0.001) and podocalyxin (AUC = 0.744, p = 0.001), and decreasing haemoglobin levels (AUC = 0.653, p = 0.016) were significantly associated with diabetic nephropathy among PLWD. At a cut‐off ≥ 12.46, nephrin emerged as the best biomarker for detecting diabetic nephropathy with higher sensitivity and specificity. Conclusions: Urinary podocyte markers, particularly nephrin, together with haematological indices, could provide sensitive yet inexpensive biomarkers for potentially predicting and diagnosing early diabetic nephropathy. Further studies are needed to augment the findings of this study.
10 October 2026 in Health Science Reports
MAMax Efui Annani‐Akollor
Background and Aim: Type 2 diabetes mellitus (T2DM) is associated with systemic inflammation and altered hematological function, including changes in red cell indices and platelet hyperreactivity. While glycosylated hemoglobin (HbA1c) is the gold standard for monitoring glycemic control, its cost and susceptibility to conditions like anemia highlight the need for accessible, reliable alternative biomarkers, particularly for identifying patients with poor glycemic control (HbA1c ≥ 7.0%). This case‐control study, therefore, investigated the utility of red cell and platelet indices as potential biomarkers of poor glycemic control in Ghanaian T2DM patients. Methods: This study recruited 134 people living with T2DM and 134 nondiabetic controls. Cases were categorized into groups with poor glycemic control (HbA1c ≥ 7.0%) and good glycemic control (HbA1c < 7.0%). HbA1c was measured using an automated analyzer, and hematological indices were measured using a Sysmex XN 2000 analyzer. Statistical analyses were performed in R Language and SPSS version 26 at a significance level of 0.05% and 95% confidence interval employing a logistic prediction model. Results: Prevalence of poor glycemic control was 60.9%. Cases with poor glycemic control had significantly lower red cell indices such as hemoglobin, hematocrit, red blood cells count, and MCV, but a higher MPV compared to controls ( p < 0.05). Multivariate logistics regression showed increasing hemoglobin levels (aOR: 0.40, 95% CI: [0.11–0.78]; p = 0.0130) and hematocrit (aOR: 0.03, 95% CI: [0.01–0.92]; p = 0.0140) were independently associated with decreased likelihood of poor glycemic control, whiles increasing MPV (aOR: 1.15, 95% CI: [1.02–3.09]; p = 0.0440) demonstrated an independent association with increased likelihood of poor glycemic control. Conclusion: Hemoglobin level, hematocrit, and mean platelet volume are significantly associated with, and can potentially serve as independent predictors of poor glycemic control. These routine, cost‐effective hematological parameters could be incorporated into risk assessment and management protocols for T2DM in resource‐limited settings.